谷氨酸与GABA比值变化是否与抑郁严重度变化相关:一项随机双盲临床试验
该随机双盲临床试验利用质子磁共振波谱(1H-MRS)在8周艾司西酞普兰或安慰剂治疗前后测量前扣带回皮层Glx/GABA,未发现Glx、GABA或Glx/GABA百分比变化与HDRS17百分比变化之间存在显著关系,且治疗前后MDD严重度与ACC Glx/GABA不相关。
要点
- 8周艾司西酞普兰或安慰剂治疗前后,ACC Glx/GABA变化与HDRS17变化无显著关系。
- 无论治疗类型如何,Glx、GABA或Glx/GABA百分比变化与HDRS17百分比变化均无显著关系。
- 治疗前后MDD严重度与ACC Glx/GABA不相关。
核心结论
- 未检测到Glx、GABA或Glx/GABA百分比变化与HDRS17百分比变化之间的显著关系,无论治疗类型如何。
- 治疗前后MDD严重度与ACC Glx/GABA不相关。
研究设计与样本
- 采用受试者内设计的随机临床试验,使用1H-MRS在8周艾司西酞普兰或安慰剂治疗前后检查Glx/GABA。
- 参与者完成17项汉密尔顿抑郁量表(HDRS17)并在治疗前后进行磁共振波谱检查。
主要发现
- 未检测到Glx、GABA或Glx/GABA百分比变化与HDRS17百分比变化之间的显著关系,无论治疗类型如何。
- 治疗前后MDD严重度与ACC Glx/GABA不相关。
关键数值与推荐
- 使用线性混合模型评估HDRS17变化与Glx/GABA变化的关系,采用单变量线性回归、纳入治疗类型作为协变量的多元线性回归及贝叶斯因子(BF)假设检验。
临床怎么用
- 原文未提出具体临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous proton magnetic resonance spectroscopy (1H-MRS) studies suggest a perturbation in glutamate and/or GABA in Major Depressive Disorder (MDD). However, no studies examine the ratio of glutamate and glutamine (Glx) to GABA (Glx/GABA) as it relates to depressive symptoms, which may be more sensitive than either single metabolite. Using a within-subject design, we hypothesized that reduction in depressive symptoms correlates with reduction in Glx/GABA in the anterior cingulate cortex (ACC). The present trial is a randomized clinical trial that utilized 1H-MRS to examine Glx/GABA before and after 8 weeks of escitalopram or placebo. Participants completed the 17-item Hamilton Depression Rating Scale (HDRS17) and underwent magnetic resonance spectroscopy before and after treatment. Two GABA-edited MEGA-PRESS acquisitions were interleaved with a water unsuppressed reference scan. GABA and Glx were quantified from the average difference spectrum, with preprocessing using Gannet and spectral fitting using TARQUIN. Linear mixed models were utilized to evaluate relationships between change in HDRS17 and change in Glx/GABA using a univariate linear regression model, multiple linear regression incorporating treatment type as a covariate, and Bayes Factor (BF) hypothesis testing to examine strength of evidence. No significant relationship was detected between percent change in Glx, GABA, or Glx/GABA and percent change in HDRS17, regardless of treatment type. Further, MDD severity before/after treatment did not correlate with ACC Glx/GABA. In light of variable findings in the literature and lack of association in our investigation, future directions should include evaluating glutamate and glutamine individually to shed light on the underpinnings of MDD severity. Advancing Personalized Antidepressant Treatment Using PET/MRI, ClinicalTrials.gov, NCT02623205.
引用
- Narayan GA, Hill KR, Wengler K, et al. Does the change in glutamate to GABA ratio correlate with change in depression severity? A randomized, double-blind clinical trial. Mol Psychiatry. 2022. PMID: 35982258. doi:10.1038/s41380-022-01730-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。